At Inotiv, our comprehensive Drug Metabolism and Pharmacokinetics (DMPK) capabilities are built on a foundation of personalized study design, quick turnaround, and unparalleled expertise. We understand the unique challenges and varying needs of our clients in the pharmaceutical and biotechnology industries. Benefit from our world-class team of scientists and 40+ year track record of providing leading pharma and biotech companies with attentive, decisive analytical services yielding high-quality data.
Our tailored drug discovery packages, designed to suit each stage of development, equip you with the necessary solutions and insights for making well-informed decisions.
To talk to an expert about our DMPK services, please click here.
Whatever the source of your data, we will perform PK-TK analyses to evaluate dose, DDI potential, bioequivalence/bioavailability, and/or clinical PK projections.
You benefit from:
Download our webinar, DMPK and PD at Inotiv—Moving at the Speed of Discovery, for valuable insight into Inotiv's capabilities within drug metabolism and pharmacokinetics (DMPK).
Featured speakers include Inotiv's industry experts Roger Melton, Vice President of Laboratory Sciences (left), and Jeanne Rumsey, Senior Principal Scientist for DMPK and Biotransformation Lead (right).
Drug Metabolism and Pharmacokinetics (DMPK) is a field in pharmacology and toxicology that focuses on how drugs and foreign substances are processed in the human body. It involves biotransformation, which is the process of metabolically transforming a drug or chemical compound.
Biotransformation: It refers to the modification or transformation of a drug or foreign substance within the body. Enzymes, especially in the liver, carry out this process, converting the original compound into various metabolites. Biotransformation alters the chemical structure, making it more water-soluble and aiding its elimination from the body.
Phase I Metabolism: In this phase, enzymes like cytochrome P450 catalyze reactions like oxidation, reduction, and hydrolysis. These reactions introduce or expose functional groups on the drug molecule, making it more amenable to further modification.
Phase II Metabolism: Phase II reactions involve the conjugation of the drug or its Phase I metabolites with endogenous molecules like glucuronic acid, sulfate, glutathione, or amino acids. This conjugation makes the molecules more water-soluble, facilitating their excretion through urine or bile.
Absorption: PK examines how a drug is absorbed into the bloodstream, considering factors such as the route of administration, chemical properties, and interactions with the gastrointestinal tract.
Distribution: After absorption, PK studies how the drug is distributed throughout the body, considering factors like tissue permeability and blood flow.
Metabolism: Biotransformation is crucial in PK as it determines how a drug is metabolized in the body. Understanding the enzymes involved and the potential formation of active or toxic metabolites is essential.
Excretion: PK assesses how a drug is eliminated from the body, often through the liver, kidneys, or other routes. The rate of excretion determines the drug's half-life and dosing schedules.
DMPK is significant in toxicology, helping toxicologists understand the toxicokinetics of chemicals or drugs. This involves studying how toxic substances are absorbed, distributed, metabolized, and excreted in the body, with the focus on determining exposure levels that may lead to adverse effects.
Inotiv offers cell and molecular biology services, including gene expression and biomarker analysis, cell-based assays, and protein characterization. Our cutting-edge technology helps validate drug targets and assess therapeutic effects, providing high-quality data and tailored solutions.
Copyright © 2024 Inotiv. All Rights Reserved.